Daniel Sherbenou is an Oncology physician affiliated with University of Colorado Anschutz Medical Campus. OpenAlex indexes 210 publications with 2,104 citations (h-index 22); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1665 Aurora Ct
1665 Aurora Court Mail Stop F754
Aurora, CO 800452517
Telephone
803-213-2731Provider last certified this registry record 17 Apr 2023.
Clinical trials
- Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)
Sponsor: University of Colorado, Denver
- Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
Sponsor: University of Colorado, Denver
- CC-486 and Venetoclax for Acute Myeloid Leukemia
Sponsor: University of Colorado, Denver
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20252 payments
- GENZYME CORPORATIONProgram year20251 payment
- ABBVIE INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
45.2%Thalidomide Analog42%Lenalidomide42%Revlimid39%Pomalyst19%Part D≥26 patientsLeukocyte Growth Factor1.8%Zarxio100%Part D<11 patients+ 1 more class in this area
Dermatology
20.9%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor20.9%Acyclovir100%Part D≥63 patientsNervous system
13.3%SSRI4.7%Trazodone Hcl61%Sertraline Hcl40%Part D<11 patientsOpioid Agonist3%Oxycodone Hcl100%Part D≥11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2018–2022 per NIH RePORTER. The latest:
- Targeting Cancer Initiating Cells in Multiple Myeloma
University of Colorado Denver
FY2022$221,856K08CA222704 - Targeting Cancer Initiating Cells in Multiple Myeloma
University of Colorado Denver
FY2021$221,856K08CA222704 - Targeting Cancer Initiating Cells in Multiple Myeloma
University of Colorado Denver
FY2020$221,856K08CA222704
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025
Journal of the National Comprehensive Cancer Network
2025 - Longitudinal multi-omic profiling uncovers immune escape and predictors of response in multiple myeloma
bioRxiv (Cold Spring Harbor Laboratory)
2025 - Ribosome Profiling Reveals Translational Reprogramming via mTOR Activation in Omacetaxine-Resistant Multiple Myeloma
Molecular Cancer Research
2025 - Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Schulick, MD, MBA
University of Colorado Anschutz Medical Campus
John Rumsfeld, MD, PhD
University of Colorado Anschutz Medical Campus
Robert Eckel, MD
University of Colorado Anschutz Medical Campus
Marc Bonaca, MD
University of Colorado Anschutz Medical Campus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”